Evidence map›Paper›PMID 34891161›Full record

ArticleGigaScience2021

Fusion transcripts and their genomic breakpoints in polyadenylated and ribosomal RNA-minus RNA sequencing data.

Youri Hoogstrate, Malgorzata A Komor, René Böttcher, Job van Riet, Harmen J G van de Werken, Stef van Lieshout, Ralf Hoffmann, Evert van den Broek, Anne S Bolijn, Natasja Dits and 18 more

Open access · goldAbstract read
In one paragraph

Article in GigaScience, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.0field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 13 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

28 authors at 12 institutions in 5 countries.

Youri HoogstrateDepartment of Urology, Erasmus Medical Center Cancer Institute, Wytemaweg 80, Rotterdam 3015GD, The Netherlands.ORCID 0000-0003-2166-0676
Malgorzata A KomorDepartment of Pathology, Netherlands Cancer Institute, Amsterdam 3015GD, The Netherlands.ORCID 0000-0002-2983-1639
René BöttcherDepartment of Urology, Erasmus Medical Center Cancer Institute, Wytemaweg 80, Rotterdam 3015GD, The Netherlands.ORCID 0000-0001-8581-3876
Job van RietDepartment of Medical Oncology, Erasmus Medical Center, Rotterdam 3015GD, The Netherlands.ORCID 0000-0001-7767-7923
Harmen J G van de WerkenDepartment of Urology, Erasmus Medical Center Cancer Institute, Wytemaweg 80, Rotterdam 3015GD, The Netherlands.ORCID 0000-0002-9794-1477
Stef van LieshoutHartwig Medical Foundation, Amsterdam 1098XH, The Netherlands.
Ralf HoffmannPhilips Research, Eindhoven 5656AE, The Netherlands.ORCID 0000-0002-6285-8673
Evert van den BroekDepartment of Pathology, Netherlands Cancer Institute, Amsterdam 3015GD, The Netherlands.
Anne S BolijnDepartment of Pathology, Netherlands Cancer Institute, Amsterdam 3015GD, The Netherlands.
Natasja DitsDepartment of Urology, Erasmus Medical Center Cancer Institute, Wytemaweg 80, Rotterdam 3015GD, The Netherlands.
Daoud SieDepartment of Pathology, Netherlands Cancer Institute, Amsterdam 3015GD, The Netherlands.ORCID 0000-0001-6762-2582
David van der MeerGenomeScan, Leiden 2333BZ, The Netherlands.
Floor PepersGenomeScan, Leiden 2333BZ, The Netherlands.
Chris H BangmaDepartment of Urology, Erasmus Medical Center Cancer Institute, Wytemaweg 80, Rotterdam 3015GD, The Netherlands.ORCID 0000-0002-7787-1969
Geert J L H van LeendersDepartment of Pathology, Erasmus Medical Center, Rotterdam 3015GD, The Netherlands.ORCID 0000-0003-2176-9102
Marcel SmidDepartment of Medical Oncology, Erasmus Medical Center, Rotterdam 3015GD, The Netherlands.ORCID 0000-0003-0605-1901
Pim J FrenchDepartment of Neurology, Erasmus Medical Center Cancer Institute, Wytemaweg 80, Rotterdam 3015GD, The Netherlands.ORCID 0000-0002-0668-9529
John W M MartensDepartment of Medical Oncology, Erasmus Medical Center, Rotterdam 3015GD, The Netherlands.
Wilbert van WorkumLimes Innovations, Ruigekade 1, Leiderdorp 2351SX, The Netherlands.
Peter J van der SpekDepartment of Pathology, Erasmus Medical Center, Rotterdam 3015GD, The Netherlands.
Bart JanssenGenomeScan, Leiden 2333BZ, The Netherlands.
Eric CaldenhovenLygature, Utrecht 3521AL, The Netherlands.
Christian RauschBioLizard N.V., Ghent 9000, Belgium.
Mark de JongVHLGenetics, Wageningen 6708PW, The Netherlands.
Andrew P StubbsDepartment of Pathology, Erasmus Medical Center, Rotterdam 3015GD, The Netherlands.
Gerrit A MeijerDepartment of Pathology, Netherlands Cancer Institute, Amsterdam 3015GD, The Netherlands.
Remond J A FijnemanDepartment of Pathology, Netherlands Cancer Institute, Amsterdam 3015GD, The Netherlands.ORCID 0000-0003-2076-5521
Guido W JensterDepartment of Urology, Erasmus Medical Center Cancer Institute, Wytemaweg 80, Rotterdam 3015GD, The Netherlands.ORCID 0000-0002-8658-2552
Erasmus MC · NLErasmus MC Cancer Institute · NLThe Netherlands Cancer Institute · NLGenomeScan (Netherlands) · NLBarcelona Supercomputing Center · ESGhent University · BEHartwig Medical Foundation · NLHealth Innovations (United States) · USLygature · NLNXP (Netherlands) · NLUniversity Medical Center Groningen · NLWageningen University & Research · NL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundFusion genes are typically identified by RNA sequencing (RNA-seq) without elucidating the causal genomic breakpoints. However, non-poly(A)-enriched RNA-seq contains large proportions of intronic reads that also span genomic breakpoints.

resultsWe have developed an algorithm, Dr. Disco, that searches for fusion transcripts by taking an entire reference genome into account as search space. This includes exons but also introns, intergenic regions, and sequences that do not meet splice junction motifs. Using 1,275 RNA-seq samples, we investigated to what extent genomic breakpoints can be extracted from RNA-seq data and their implications regarding poly(A)-enriched and ribosomal RNA-minus RNA-seq data. Comparison with whole-genome sequencing data revealed that most genomic breakpoints are not, or minimally, transcribed while, in contrast, the genomic breakpoints of all 32 TMPRSS2-ERG-positive tumours were present at RNA level. We also revealed tumours in which the ERG breakpoint was located before ERG, which co-existed with additional deletions and messenger RNA that incorporated intergenic cryptic exons. In breast cancer we identified rearrangement hot spots near CCND1 and in glioma near CDK4 and MDM2 and could directly associate this with increased expression. Furthermore, in all datasets we find fusions to intergenic regions, often spanning multiple cryptic exons that potentially encode neo-antigens. Thus, fusion transcripts other than classical gene-to-gene fusions are prominently present and can be identified using RNA-seq.

conclusionBy using the full potential of non-poly(A)-enriched RNA-seq data, sophisticated analysis can reliably identify expressed genomic breakpoints and their transcriptional effects.

Indexed as

GenomicsRNA, RibosomalGene FusionGenomeSequence Analysis, RNARNA, Ribosomalchromosome breakagecryptic exonsgene fusiongenomic structural variationRNA precursorsRNA-seqTMPRSS2-ERG

Identifiers

PMID34891161
PMCPMC8673554
OpenAlexW4200124850

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.